{"DataElement":{"publicId":"6077839","version":"1","preferredName":"Treatment Cohort Study EC10130 Code","preferredDefinition":"The code that represents the information pertaining to protocol EC10130 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_EC10130_CD","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"2497526","version":"1","preferredName":"Treatment Cohort Study","preferredDefinition":"Information pertaining to studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.","longName":"TX_COHORT_STDY","context":"DCP","contextVersion":"1","ObjectClass":{"publicId":"2416951","version":"1","preferredName":"Therapy","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"02DBEE3F-243E-103A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-12","modifiedBy":"ONEDATA","dateModified":"2005-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2497524","version":"1","preferredName":"Cohort Study","preferredDefinition":"Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.","longName":"C15208","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cohort Study","conceptCode":"C15208","definition":"A research study that compares a particular outcome (such as lung cancer) in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"191BBE49-FC9E-4C77-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-07-21","modifiedBy":"ONEDATA","dateModified":"2006-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"191BBE49-FCAF-4C77-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-07-21","modifiedBy":"SOKKERL","dateModified":"2017-05-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6077833","version":"1","preferredName":"EC10130 Cohort Code","preferredDefinition":"A group of individuals, identified by a common characteristic._A symbol or combination of symbols which is assigned to the members of a collection.","longName":"6077833v1.0","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"250","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"A - DL1","valueDescription":"Cohort A - DL1: Cycle 1: Tazemetostat 800 mg PO once on day 1, then 800 mg PO BID days 2-28 Cycle 2+: Tazemetostat 800 mg PO BIDBID","ValueMeaning":{"publicId":"6141604","version":"1","preferredName":"Cohort A - DL1: Cycle 1: Tazemetostat 800 mg PO once on day 1, then 800 mg PO BID days 2-28 Cycle 2+: Tazemetostat 800 mg PO BIDBID","longName":"6141604","preferredDefinition":"Cohort A - DL1: Cycle 1: Tazemetostat 800 mg PO once on day 1, then 800 mg PO BID days 2-28 Cycle 2+: Tazemetostat 800 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67C666B5-E241-45BB-E053-F662850A7B8C","latestVersionIndicator":"Yes","beginDate":"2018-03-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-19","modifiedBy":"SOKKERL","dateModified":"2018-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6805E7F4-6566-4BA0-E053-F662850A94A1","beginDate":"2018-03-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-22","modifiedBy":"ONEDATA","dateModified":"2018-03-22","deletedIndicator":"No"},{"value":"B - DL1","valueDescription":"Cohort B - DL1: Cycle 1: Tazemetostat 800 mg PO once on day 1, then 800 mg PO BID days 2-28 Cycle 2+: Tazemetostat 800 mg PO BID","ValueMeaning":{"publicId":"6141603","version":"1","preferredName":"Cohort B - DL1: Cycle 1: Tazemetostat 800 mg PO once on day 1, then 800 mg PO BID days 2-28 Cycle 2+: Tazemetostat 800 mg PO BID","longName":"6141603","preferredDefinition":"Cohort B  - DL1: Cycle 1: Tazemetostat 800 mg PO once on day 1, then 800 mg PO BID days 2-28 Cycle 2+: Tazemetostat 800 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67C666B5-E21E-45BB-E053-F662850A7B8C","latestVersionIndicator":"Yes","beginDate":"2018-03-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-19","modifiedBy":"SOKKERL","dateModified":"2018-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6805E7F4-657C-4BA0-E053-F662850A94A1","beginDate":"2018-03-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-22","modifiedBy":"ONEDATA","dateModified":"2018-03-22","deletedIndicator":"No"},{"value":"C - DL1","valueDescription":"Cohort C - DL1: Cycle 1: Tazemetostat 600 mg PO once on day 1, then 600 mg PO BID days 2-28 Cycle 2+: Tazemetostat 600 mg PO BID","ValueMeaning":{"publicId":"6141602","version":"1","preferredName":"Cohort C - DL1: Cycle 1: Tazemetostat 600 mg PO once on day 1, then 600 mg PO BID days 2-28 Cycle 2+: Tazemetostat 600 mg PO BID","longName":"6141602","preferredDefinition":"Cohort C - DL1: Cycle 1: Tazemetostat 600 mg PO once on day 1, then 600 mg PO BID days 2-28 Cycle 2+: Tazemetostat 600 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67C666B5-E1FB-45BB-E053-F662850A7B8C","latestVersionIndicator":"Yes","beginDate":"2018-03-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-19","modifiedBy":"SOKKERL","dateModified":"2018-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6806AA22-1624-03E6-E053-F662850AB9AC","beginDate":"2018-03-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-22","modifiedBy":"ONEDATA","dateModified":"2018-03-22","deletedIndicator":"No"},{"value":"C - DL2","valueDescription":"Cohort C - DL2 Cycle 1: Tazemetostat 800 mg PO once on day 1, then 800 mg PO BID days 2-28 Cycle 2+: Tazemetostat 800 mg PO BID","ValueMeaning":{"publicId":"6141600","version":"1","preferredName":"Cohort C - DL2 Cycle 1: Tazemetostat 800 mg PO once on day 1, then 800 mg PO BID days 2-28 Cycle 2+: Tazemetostat 800 mg PO BID","longName":"6141600","preferredDefinition":"Cohort C - DL2 Cycle 1: Tazemetostat 800 mg PO once on day 1, then 800 mg PO BID days 2-28 Cycle 2+: Tazemetostat 800 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67C666B5-E1B5-45BB-E053-F662850A7B8C","latestVersionIndicator":"Yes","beginDate":"2018-03-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-19","modifiedBy":"SOKKERL","dateModified":"2018-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6806AA22-163A-03E6-E053-F662850AB9AC","beginDate":"2018-03-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-22","modifiedBy":"ONEDATA","dateModified":"2018-03-22","deletedIndicator":"No"},{"value":"D  - DL1","valueDescription":"Cohort D - DL1: Cycle 1: Tazemetostat 400 mg PO once on day 1, then 400 mg PO BID days 2-28 Cycle 2+: Tazemetostat 400 mg PO BID","ValueMeaning":{"publicId":"6141601","version":"1","preferredName":"Cohort D - DL1: Cycle 1: Tazemetostat 400 mg PO once on day 1, then 400 mg PO BID days 2-28 Cycle 2+: Tazemetostat 400 mg PO BID","longName":"6141601","preferredDefinition":"Cohort D - DL1:  Cycle 1: Tazemetostat 400 mg PO once on day 1, then 400 mg PO BID days 2-28 Cycle 2+: Tazemetostat 400 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67C666B5-E1D8-45BB-E053-F662850A7B8C","latestVersionIndicator":"Yes","beginDate":"2018-03-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-19","modifiedBy":"SOKKERL","dateModified":"2018-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6806AA22-1650-03E6-E053-F662850AB9AC","beginDate":"2018-03-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-22","modifiedBy":"ONEDATA","dateModified":"2018-03-22","deletedIndicator":"No"},{"value":"D - DL2","valueDescription":"Cohort D -  DL2:  Cycle 1: Tazemetostat 600 mg PO once on day 1, then 600 mg PO BID days 2-28 Cycle 2+: Tazemetostat 600 mg PO BID","ValueMeaning":{"publicId":"6141599","version":"1","preferredName":"Cohort D -  DL2:  Cycle 1: Tazemetostat 600 mg PO once on day 1, then 600 mg PO BID days 2-28 Cycle 2+: Tazemetostat 600 mg PO BID","longName":"6141599","preferredDefinition":"Cohort D -  DL2:  Cycle 1: Tazemetostat 600 mg PO once on day 1, then 600 mg PO BID days 2-28 Cycle 2+: Tazemetostat 600 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67C666B5-E192-45BB-E053-F662850A7B8C","latestVersionIndicator":"Yes","beginDate":"2018-03-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-19","modifiedBy":"SOKKERL","dateModified":"2018-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6806D3B1-98B4-4488-E053-F662850A87E8","beginDate":"2018-03-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-22","modifiedBy":"ONEDATA","dateModified":"2018-03-22","deletedIndicator":"No"},{"value":"D - DL3","valueDescription":"Cohort D - DL3: Cycle 1: Tazemetostat 800 mg PO once on day 1, then 800 mg PO BID days 2-28 Cycle 2+: Tazemetostat 800 mg PO BID","ValueMeaning":{"publicId":"6141598","version":"1","preferredName":"Cohort D - DL3: Cycle 1: Tazemetostat 800 mg PO once on day 1, then 800 mg PO BID days 2-28 Cycle 2+: Tazemetostat 800 mg PO BID","longName":"6141598","preferredDefinition":"Cohort D - DL3: Cycle 1: Tazemetostat 800 mg PO once on day 1, then 800 mg PO BID days 2-28 Cycle 2+: Tazemetostat 800 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67C666B5-E16F-45BB-E053-F662850A7B8C","latestVersionIndicator":"Yes","beginDate":"2018-03-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-19","modifiedBy":"SOKKERL","dateModified":"2018-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6806D3B1-98CA-4488-E053-F662850A87E8","beginDate":"2018-03-19","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-03-22","modifiedBy":"ONEDATA","dateModified":"2018-03-22","deletedIndicator":"No"},{"value":"D - DL-1","valueDescription":"Cohort D - DL-1: Cycle 1: Tazemetostat 200 mg PO once on day 1, then 200 mg PO BID days 2-28 Cycle 2+: Tazemetostat 200 mg PO BID","ValueMeaning":{"publicId":"6199958","version":"1","preferredName":"Cohort D - DL-1: Cycle 1: Tazemetostat 200 mg PO once on day 1, then 200 mg PO BID days 2-28 Cycle 2+: Tazemetostat 200 mg PO BID","longName":"6199958","preferredDefinition":"Cohort D - DL-1: Cycle 1: Tazemetostat 200 mg PO once on day 1, then 200 mg PO BID days 2-28 Cycle 2+: Tazemetostat 200 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69F9CCE1-EEB6-6A0A-E053-F662850A0E94","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"69F9CCE1-EECF-6A0A-E053-F662850A0E94","beginDate":"2018-04-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","deletedIndicator":"No"},{"value":"C - DL-1","valueDescription":"Cohort C - DL-1: Cycle 1: Tazemetostat 400 mg PO once on day 1, then 400 mg PO BID days 2-28 Cycle 2+: Tazemetostat 400 mg PO BID","ValueMeaning":{"publicId":"6199959","version":"1","preferredName":"Cohort C - DL-1: Cycle 1: Tazemetostat 400 mg PO once on day 1, then 400 mg PO BID days 2-28 Cycle 2+: Tazemetostat 400 mg PO BID","longName":"6199959","preferredDefinition":"Cohort C - DL-1: Cycle 1: Tazemetostat 400 mg PO once on day 1, then 400 mg PO BID days 2-28 Cycle 2+: Tazemetostat 400 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69F9CCE1-EED9-6A0A-E053-F662850A0E94","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"69F9CCE1-EEF2-6A0A-E053-F662850A0E94","beginDate":"2018-04-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","deletedIndicator":"No"},{"value":"C - DL-2","valueDescription":"Cohort C - DL-2: Cycle 1: Tazemetostat 200 mg PO once on day 1, then 200 mg PO BID days 2-28 Cycle 2+: Tazemetostat 200 mg PO BID","ValueMeaning":{"publicId":"6199960","version":"1","preferredName":"Cohort C - DL-2: Cycle 1: Tazemetostat 200 mg PO once on day 1, then 200 mg PO BID days 2-28 Cycle 2+: Tazemetostat 200 mg PO BID","longName":"6199960","preferredDefinition":"Cohort C - DL-2: Cycle 1: Tazemetostat 200 mg PO once on day 1, then 200 mg PO BID days 2-28 Cycle 2+: Tazemetostat 200 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69F9CCE1-EEFC-6A0A-E053-F662850A0E94","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"69F9CCE1-EF15-6A0A-E053-F662850A0E94","beginDate":"2018-04-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","deletedIndicator":"No"},{"value":"B - DL-1","valueDescription":"Cohort B - DL-1: Cycle 1: Tazemetostat 600 mg PO once on day 1, then 600 mg PO BID days 2-28 Cycle 2+: Tazemetostat 600 mg PO BID","ValueMeaning":{"publicId":"6199961","version":"1","preferredName":"Cohort B - DL-1: Cycle 1: Tazemetostat 600 mg PO once on day 1, then 600 mg PO BID days 2-28 Cycle 2+: Tazemetostat 600 mg PO BID","longName":"6199961","preferredDefinition":"Cohort B - DL-1: Cycle 1: Tazemetostat 600 mg PO once on day 1, then 600 mg PO BID days 2-28 Cycle 2+: Tazemetostat 600 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69F9CCE1-EF1F-6A0A-E053-F662850A0E94","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"69F9CCE1-EF38-6A0A-E053-F662850A0E94","beginDate":"2018-04-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","deletedIndicator":"No"},{"value":"B - DL-2","valueDescription":"Cohort B - DL-2: Cycle 1: Tazemetostat 400 mg PO once on day 1, then 400 mg PO BID days 2-28 Cycle 2+: Tazemetostat 400 mg PO BID","ValueMeaning":{"publicId":"6199962","version":"1","preferredName":"Cohort B - DL-2: Cycle 1: Tazemetostat 400 mg PO once on day 1, then 400 mg PO BID days 2-28 Cycle 2+: Tazemetostat 400 mg PO BID","longName":"6199962","preferredDefinition":"Cohort B - DL-2: Cycle 1: Tazemetostat 400 mg PO once on day 1, then 400 mg PO BID days 2-28 Cycle 2+: Tazemetostat 400 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69F9CCE1-EF42-6A0A-E053-F662850A0E94","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"69F9CCE1-EF5B-6A0A-E053-F662850A0E94","beginDate":"2018-04-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"4386398","version":"1","preferredName":"Cohort Code","preferredDefinition":"A group of individuals, identified by a common characteristic.:A system of numbered categories for representation of data.","longName":"C61512:C25162","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cohort","conceptCode":"C61512","definition":"A group of individuals, identified by a common characteristic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE558C16-1C27-C6A8-E040-BB89AD430BEE","latestVersionIndicator":"Yes","beginDate":"2014-07-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-07-16","modifiedBy":"ONEDATA","dateModified":"2014-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"65AC85DA-C364-1481-E053-F662850AB051","latestVersionIndicator":"Yes","beginDate":"2018-02-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-02-20","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeDescription":"11/8/18 TT released/PClark.; Curated for Protocol 10166. LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Treatment Assignment Codes","type":"Preferred Question Text","description":"Treatment Assignment Codes","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"65AC9197-145E-7552-E053-F662850A7E6B","latestVersionIndicator":"Yes","beginDate":"2018-02-20","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-02-20","modifiedBy":"SOKKERL","dateModified":"2018-11-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}